Prosecution Insights
Last updated: November 19, 2026
Application No. 17/998,202

TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB

Non-Final OA §103§112
Filed
Nov 08, 2022
Priority
May 08, 2020 — EU 20173749.1 +3 more
Examiner
IVANOVA, SVETLANA M
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Pharmaceutica N.V.
OA Round
3 (Non-Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
435 granted / 857 resolved
-9.2% vs TC avg
Strong +52% interview lift
Without
With
+52.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
33 currently pending
Career history
888
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
14.1%
-25.9% vs TC avg
§112
22.2%
-17.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 857 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/16/2026 has been entered. Response to Arguments Claim Rejections - 35 USC § 112 In view of Applicant’s claim amendments, a new modified rejection has been made below. Claim Rejections - 35 USC § 103 Applicant has amended the claims, and made arguments against the claims as amended. In view of Applicant’s claim amendments vis-a-vie the new wherein claim limitation of claim 40, a modified rejection has been made below, which now renders Applicant’s arguments moot. Applicant has further made arguments concerning the claim term “crospovidone”. Applicant’s arguments have been further addressed in the modified rejection below. Claims 40-50, 53, 54 and 58-64 are pending, and have been examined herewith to the extent of Applicant’s elected species. Note to File on A Related Adjudicated Patent File Wrapper While res judicata has not been invoked, because the instant claims are of a somewhat different scope, the Examiner notes that claims of a similar scope were already examined and rejected by a different examiner in patent application 15/950,707, were subsequently appealed to PTAB, which in turn affirmed the other examiner in 2023, and were then further affirmed on appeal by the Federal Circuit in 2024. Some related claims of the ‘707 application are noted for the record. PNG media_image1.png 275 739 media_image1.png Greyscale PNG media_image2.png 63 672 media_image2.png Greyscale The Examiner also notes in comparison some claims in the instant application. PNG media_image3.png 291 706 media_image3.png Greyscale Claim Rejections - 35 USC § 112 (new) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 40-50, 53, 54, and 58-64 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 40 recites: PNG media_image4.png 208 682 media_image4.png Greyscale The claim is vague and indefinite, because once it is recites that the treatment is plus prednisone wherein the patient is surgically castrated, and then it recites that it is plus prednisone, if not surgically castrated. Claim 63 recites the limitations: "a)…253.2 mg lactose monohydrate, and 30 mg crospovidone" and b) a)…253.2 mg lactose monohydrate, and 32 mg crospovidone" in lines 2-6. There is insufficient antecedent basis for these limitations in the claim. Applicant’s amended claim 63, deleting the claim term “diluent”, per Applicant allegedly overcomes the lack of antecedent basis for the claim term “diluent”. However, it does not. More than that, it creates a new lack of antecedent support claim issue vis-à-vis the claimed disintegrant crospovidone. For context, the entire claim 63, and claim 40 from which it depends, are reproduced for the record. PNG media_image5.png 196 698 media_image5.png Greyscale PNG media_image6.png 208 682 media_image6.png Greyscale As can be seen from the claim amendments claim 40 did not recite a diluent, whether by claim term “diluent” or by its actual specific chemical name following up, but did recite “disintegrant”. Now Applicant has also deleted “disintegrant” from the claims further raising an antecedent base issue for the claimed ingredients by their chemical names. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 40-50, 53, 54, 58-62 and 64 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2018191141 A1 to Yu et al. (“Yu”, of record), and further in view of Zejula (niraparib) capsules, for oral use, FDA Reference ID: 4600207, initial US. Approval: 2017, revised 04/ 2020 (“FDA label for niraparib”, of record). Claim interpretation The Examiner incorporates by reference her interpretation of Applicant’s claims from the 35 U.S.C. 112(b) rejection above. Rejection Yu discloses a method for treating a prostate cancer comprising administering to a patient a therapeutically effective amount of niraparib, a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of prednisone (claim 1). The prostate cancer is hormone-sensitive or castration-resistant prostate cancer (claim 2). The prostate cancer may be metastatic ([0033]). Niraparib and abiraterone acetate are administered to the patient in a single composition, or in separate compositions (claims 3-4, [0035]). The route of administration may be oral (tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs) ([0043]). The dosing, either free dose or fixed dose are taught in paragraphs, to include specific dose of the drugs of Applicant’s claims 60 and 63. ([0035]-[0040]). The patient might have been previously treated with anti-androgens (i.e. medical castration per Applicant’s specification at para [0241]), to include for the pre-treatment times of Applicant’s claims 45-48. ([0034]). “Additionally or alternatively, the patient may have undergone at least one line of androgen receptor-targeted therapy prior to administering a first dose of the niraparib, abiraterone acetate, and prednisone. The period of time between the end of the other treatment and the administration of niraparib, abiraterone acetate, and prednisone in accordance with the present invention may be years, months, weeks, days, a single day, or less than 24 hours.” There is no indication in Yu that the patient should have undergone prior therapy with a next/ second generation androgen signaling inhibitor therapy, per Applicant’s claims 49 and 50. Yu further provides motivation to specifically test for deleterious germline or somatic HRR gene mutations in prostate cancer as a part of the treatment, such as claimed by Applicant. It discloses that niraparib is a PARP inhibitor, and that the PARP inhibitor olaparib was recently investigated in a Phase 2 study to assess efficacy and safety in patients with mCRPC post-chemotherapy and AR-targeted agents, and that genetic sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes, including, but not limited to BRCA-1/2, ATM, Fanconi anemia genes, and CHEK2 in tumor samples. ([0004]-[0006]). Even though the reference does not specifically indicate the niraparib as tosylate monohydrate and the lactose as lactose monohydrate, this was the pharmaceutical form used in therapy as to both, as exemplified by the FDA label for niraparib. (p. 16). Applicant has amended independent claim 40 to recite: “wherein the patient is surgically castrated or continues with a gonadotropin releasing hormone analog (GnRHa) therapy during the treatment with the pharmaceutical formulation, plus prednisone, if not surgically castrated.” It is noted that Yu does teach surgical castration as a means of early stage treatment of prostate cancer, and does indicate that this early therapy has a risk of failing leading to disease progression and spread. “At its early stages, localized prostate cancer is often curable with local therapy including, for example, surgical removal of the prostate gland and radiotherapy. However, when local therapy fails to cure prostate cancer, as it does in up to a third of men, the disease progresses into incurable metastatic disease (i.e., disease in which the cancer has spread from one part of the body to other parts).” ([0002]). Then it goes on to explain that there remains a need for the subset of patients with metastatic disease who do not respond initially to these treatments. “ [0003] For many years, the established standard of care for men with malignant castration-resistant prostate cancer (mCRPC) was docetaxel chemotherapy. More recently, abiraterone acetate (ZYTIGA®) in combination with prednisone has been approved for treating metastatic castrate resistant prostate cancer. Androgen receptor (AR)-targeted agents, such as enzalutamide (XTANDI®,) have also entered the market for treating metastatic castrate resistant prostate cancer. Platinum-based chemotherapy has been tested in a number of clinical studies in molecularly unselected prostate cancer patients with limited results and significant toxicities. However, there remains a subset of patients who either do not respond initially, or become refractory (or resistant) to these treatments. No approved therapeutic options are available for such patients.” Then it explicitly says that the instant invention are directed meeting this need. “[0007] However, a need remains for therapies against a prostate cancer, including hormone sensitive, hormone naive high risk, and castration-resistant prostate cancers. SUMMARY [0008] Provided herein are methods for treating a prostate cancer comprising, consisting of and/or consisting essentially of, administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, a therapeutically effective amount of a CYP17 inhibitor and a therapeutically effective amount of a glucocorticoid.” Thus, Yu explicitly makes the disclosed therapy applicable to patients with mCRPC, who have undergone surgical castration. It is noted that surgical castration is a term also known as bilater orchiectomy. (see, e.g., Applicant’s specification at [0243]). Accordingly, it would have been obvious to a person of skill in the art before the effective filing date of the claimed invention to combine the teachings of Yu and the FDA label for niraparib in order to practice Applicant’s claimed method with a reasonable expectation of success. The skilled artisan would have been motivated to do so guided by the desire to optimize the niraparib drug form with one, which has already gone through clinical testing. Even though Yu does not specifically disclose the amounts of the additional ingredients crospovidone and lactose monohydrate, it would have been obvious to a person of skill in the art before the effective filing date of the claimed invention to optimize the amounts of these ingredients with a reasonable expectation of success in order to achieve good formulation disintegration and dilution. It would have been further obvious to a person of skill in the art to practice Applicant’s claimed method in the mCSPC patient population, which has undergone surgical castration, as explicitly provided by Yu as beneficial for this particular subset of patients. Claim 63 is rejected under 35 U.S.C. 103, as applied to claims 40-50, 53, 54, 58-62 and 64 in the 35 U.S.C. 103 rejection above, as unpatentable over WO 2018191141 A1 to Yu et al. (“Yu”, of record), and further in view of Zejula (niraparib) capsules, for oral use, FDA Reference ID: 4600207, initial US. Approval: 2017, revised 04/ 2020 (“FDA label for niraparib”, of record), and as further evidenced by US 20230046317 A1 to Ye (“Ye”). Claim interpretation The Examiner incorporates by reference her interpretation of Applicant’s claims from the 35 U.S.C. 112(b) rejection above. Rejection Yu and the FDA label for niraparib are discussed in the 35 USC rejection above. Yu further discloses that the composition may further contain additional excipients, such as disintegrating agents ([0043]), and names as an additional excipient polyvinyl polypyrrolidone ([0043], [0046]). It is noted that polyvinyl polypyrrolidone is an alternative name for crospovidone. Yu further discloses that additional ingredients include diluents, such as lactose. ([0043]). Applicant has disputed that “polyvinyl polypyrrolidone is an alternative name for crospovidone”, saying that crospovidone is instead polyvinyl polypyrrolidone. The Examiner does not disagree with Applicant that crospovidone is also known as polyvinyl polypyrrolidone. However, crospovidone is further called as well “polyvinyl polypyrrolidone” by persons of skill in the art. See, e.g. Ye at [0011]- “polyvinyl N-pyrrolidone (crospovidone)”.1 Accordingly, it would have been obvious to a person of skill in the art before the effective filing date of the claimed invention to combine the teachings of Yu, the FDA label for niraparib and Ye, in order to practice the method of Applicant’s claim 63 with a reasonable expectation of success. This is because the additionally claimed excipients in it are further known in the art in combination with Applicant’s claimed ingredients. As crosspovidone is knows as all of, inter alia, polyvinyl polypyrrolidone, crosslinked polyvinyl polypyrrolidone and polyvinyl polypyrrolidone, among names, the skilled artisan would have been further motivated to optimize the composition with different forms of the compounds (crosslinked or not), as well as to optimize the amounts of it, as these are result-effective variables, which are subject to optimization for creating an optimum pharmaceutical formulation for proper dilution and disintegration. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SVETLANA M IVANOVA whose telephone number is (571)270-3277. The examiner can normally be reached 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L. Klinkel can be reached at (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SVETLANA M IVANOVA/ Primary Examiner, Art Unit 1627 1 A way to understand this is that crospovidone is a crosslinked form of polyvinyl pyrrolidone. See, e.g., US 20230218640 A1 to Quinten et al.- “crospovidone (crosslinked polyvinylpyrrolidone”, e.g., commercially available as Kollidon CL-F and Polyplasdone XL-10)”.
Read full office action

Prosecution Timeline

Nov 08, 2022
Application Filed
Feb 03, 2026
Non-Final Rejection mailed — §103, §112
Apr 29, 2026
Response Filed
May 21, 2026
Final Rejection mailed — §103, §112
Oct 16, 2026
Request for Continued Examination
Oct 19, 2026
Response after Non-Final Action
Nov 12, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788012
SUBSTITUTED TOLYL FUNGICIDES AND THEIR MIXTURES
4y 0m to grant Granted Nov 10, 2026
Patent 12778943
PHARMACEUTICAL COMPOSITION COMPRISING AN INDACATEROL COMPOUND, A PHARMACEUTICALLY ACCEPTABLE SALT OF GLYCOPYRROLATE AND 1,1-DIFLUOROETHANE
4y 9m to grant Granted Nov 03, 2026
Patent 12778940
AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
4y 0m to grant Granted Nov 03, 2026
Patent 12766133
COMPOSITIONS AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER
3y 11m to grant Granted Oct 20, 2026
Patent 12758520
GLYCERYLTRIACETATE (GTA) FOR USE IN IMPROVING BREATHING
3y 11m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
99%
With Interview (+52.0%)
2y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 857 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month